VMXC-001 is under clinical development by VarmX and currently in Phase I for Blood Coagulation. According to GlobalData, Phase I drugs for Blood Coagulation does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VMXC-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VMXC-001 overview
VMX-C001 is under development for the treatment of severe bleeding in patients taking factor Xa inhibitors. PseudoXa is a factor Xa inhibitor reversal agent. The drug candidate is a modified form of recombinant human coagulation factor X based on snake venom properties intended to restore blood clotting in patients taking coagulation inhibitors. It is administered through intravenous route.
See Also:
VarmX overview
VarmX produces PseudoXa medicine. It helps to restore hemostasis in case of bleeding or emergency surgery in patients. It is headquartered in Leiden, Zuid-Holland, The Netherlands.
For a complete picture of VMXC-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
